JACC. Cardiovascular interventions · 2026
Long-Term Outcomes in Patients With New-Onset Left Bundle Branch Block Following TAVR.
СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Benavent-García Carla, Avvedimento Marisa, Cepas-Guillén Pedro, Collado-Macián Carlos, Hernando Del Portillo Juan, Vidal-Cales Pablo, Giuliani Carlos, Mohammadi Siamak, Philippon François, Rodés-Cabau Josep
Аннотация
BACKGROUND: New-onset persistent left bundle branch block (NOP-LBBB) is a frequent conduction disturbance following transcatheter aortic valve replacement (TAVR), yet its long-term prognostic significance remains uncertain.
OBJECTIVES: The aim of this study was to assess the impact of NOP-LBBB on long-term (up to 10 years) clinical and echocardiographic outcomes after TAVR.
METHODS: A total of 1,052 consecutive patients without preprocedural LBBB or permanent pacemaker implantation were included. NOP-LBBB was defined as new LBBB following TAVR persisting at discharge. Clinical and echocardiographic outcomes were prospectively collected in a dedicated database, and the median follow-up duration was 5 years (Q1-Q3: 3-6 years).
RESULTS: NOP-LBBB occurred in 312 patients (29.6%). Compared with patients without NOP-LBBB, those with NOP-LBBB had a higher incidence of the composite endpoint of cardiovascular mortality or heart failure hospitalization (37.5% vs 31.5%; adjusted HR [aHR]: 1.37; 95% CI: 1.09-1.73; P = 0.007). This difference was driven primarily by an increased cardiovascular mortality risk (30.5% vs 23.8%; aHR: 1.46; 95% CI: 1.12-1.89; P = 0.004), including a higher rate of sudden death in the NOP-LBBB group (4.2% vs 1.5%, aHR: 3.52; 95% CI: 1.53-8.14; P = 0.003). A higher incidence of left ventricular ejection fraction decline (≥10%) was observed in the NOP-LBBB group (P = 0.025) with no differences in heart failure hospitalization between groups (P = 0.243).
CONCLUSIONS: NOP-LBBB following TAVR was associated with adverse long-term outcomes, including cardiovascular mortality, sudden death, and progressive left ventricular dysfunction. These findings underscore the need for tailored follow-up and risk stratification in this high-risk subgroup.
OBJECTIVES: The aim of this study was to assess the impact of NOP-LBBB on long-term (up to 10 years) clinical and echocardiographic outcomes after TAVR.
METHODS: A total of 1,052 consecutive patients without preprocedural LBBB or permanent pacemaker implantation were included. NOP-LBBB was defined as new LBBB following TAVR persisting at discharge. Clinical and echocardiographic outcomes were prospectively collected in a dedicated database, and the median follow-up duration was 5 years (Q1-Q3: 3-6 years).
RESULTS: NOP-LBBB occurred in 312 patients (29.6%). Compared with patients without NOP-LBBB, those with NOP-LBBB had a higher incidence of the composite endpoint of cardiovascular mortality or heart failure hospitalization (37.5% vs 31.5%; adjusted HR [aHR]: 1.37; 95% CI: 1.09-1.73; P = 0.007). This difference was driven primarily by an increased cardiovascular mortality risk (30.5% vs 23.8%; aHR: 1.46; 95% CI: 1.12-1.89; P = 0.004), including a higher rate of sudden death in the NOP-LBBB group (4.2% vs 1.5%, aHR: 3.52; 95% CI: 1.53-8.14; P = 0.003). A higher incidence of left ventricular ejection fraction decline (≥10%) was observed in the NOP-LBBB group (P = 0.025) with no differences in heart failure hospitalization between groups (P = 0.243).
CONCLUSIONS: NOP-LBBB following TAVR was associated with adverse long-term outcomes, including cardiovascular mortality, sudden death, and progressive left ventricular dysfunction. These findings underscore the need for tailored follow-up and risk stratification in this high-risk subgroup.